Frederic Ors
Angel Investor
Frederic Ors is a seed investor focused on Medical and Health Care. Fred has served as our Chief Executive Officer since April 2016. As CEO, he has led the transformation of IMV into a leading clinical-stage immune-oncology company with world-class collaborators and a strong scientific foundation. He has more than 21 years of experience in the biopharmaceutical industry, having served in several managementpositions encompassing business development, intellectual property, strategic planning, pre-marketing, and communication. Before joining IMV, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013.Fred is also a Director of CQDM, a biopharmaceutical research consortium and served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, Fred was Licensing Manager at the University Paris VII-Denis Diderot, one of the largest sciences and medical university in France. He owns a BSc degree in Biology and a Master’s degree in Biotechnology and Business Management from the University of Angers (France).
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Frederic Ors invests in
Stages Frederic Ors invests in
Countries Frederic Ors invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Saguaro offers new drug discovery technologies that help fight human disease. Their unique products help drug developers make the most of their in vitro models, with the goal of generating new data that is more predictive of results in clinical trials with humans. | $1.1M / Seed / Feb 16, 2022 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Frederic Ors invest in?
Frederic Ors invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Frederic Ors?
Public channels for Frederic Ors include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Frederic Ors last invest?
The most recent investment recorded for Frederic Ors closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
